Peptides & Proteins

Challenge: A newly-formed US biotech company has acquired the intellectual property and assets of a legacy cancer vaccine company that had ceased trading several years ago following disappointing...

Challenge: A biotech client had developed a generic version of a major anti-diabetic peptide drug, and wanted a clearer understanding of the product's registrability, as well as support with defining...

Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in the...

Challenge: Our client was developing an oral form of an approved biologic drug which appeared to have excellent properties in terms of a rapid time to maximum concentration in the blood. A Phase II...

Challenge: A university research group had discovered a new pathway for regulation of T cell trafficking in the inflammatory response. The group had also identified an anti-inflammatory peptide and...

Challenge A small biotech company was developing a peptide and needed support in taking the compound to first-in-man studies and Phase II clinical trials. This was the first time the company had...